down arrow

Humacyte, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US44486Q1031
USD
0.85
0.07 (8.61%)

Mar 23

NAS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
bluebird bio, Inc.
MaxCyte, Inc.
Humacyte, Inc.
uniQure NV
Precigen, Inc.
Voyager Therapeutics, Inc.
Terns Pharmaceuticals, Inc.
Lyell Immunopharma, Inc.
Aura Biosciences, Inc.
Aldeyra Therapeutics, Inc.
Renovaro, Inc.

Why is Humacyte, Inc. ?

1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
  • Poor long term growth as Net Sales has grown by an annual rate of 23.55% and Operating profit at -195.80% over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -13.82
2
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -74.39%, its profits have risen by 0.9%
3
Consistent Underperformance against the benchmark over the last 3 years
  • Along with generating -74.39% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Humacyte, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Humacyte, Inc.
-74.39%
-0.74
119.27%
S&P 500
16.12%
0.84
19.28%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
23.55%
EBIT Growth (5y)
-195.80%
EBIT to Interest (avg)
-13.82
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.18
Sales to Capital Employed (avg)
0.03
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
51.97%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-45.50
EV to EBIT
-2.09
EV to EBITDA
-2.24
EV to Capital Employed
-219.94
EV to Sales
140.00
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

11What is working for the Company
NET SALES(9M)

Higher at USD 1.57 MM

DEBT-EQUITY RATIO (HY)

Lowest at -651.21 %

DEBTORS TURNOVER RATIO(HY)

Highest at 2.91 times

NET PROFIT(Q)

Highest at USD -26.41 MM

-4What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at USD -105.49 MM

RAW MATERIAL COST(Y)

Grown by 18,220% (YoY

Here's what is working for Humacyte, Inc.

Net Sales
At USD 1.57 MM has Grown at inf%
Year on Year (YoY)
MOJO Watch
Sales trend is very positive

Net Sales (USD MM)

Net Profit
Highest at USD -26.41 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

Debt-Equity Ratio
Lowest at -651.21 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio
Highest at 2.91 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Net Sales
Higher at USD 1.57 MM
than preceding 12 month period ended Sep 2025
MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months

Net Sales (USD MM)

Depreciation
Highest at USD 1.86 MM
in the last five periods
MOJO Watch
The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for Humacyte, Inc.

Operating Cash Flow
Lowest at USD -105.49 MM and Fallen
In each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Raw Material Cost
Grown by 18,220% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Download on App Store
Get it on Google Play
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."